牛牛AI助理已提取核心訊息
On February 28, 2024, 180 Life Sciences Corp. announced the appointment of Blair Jordan to its Board of Directors. Jordan, deemed independent according to Nasdaq Capital Market rules, will serve as a Class II director until the 2024 Annual Meeting of Stockholders. Concurrently, the Board set its membership at four and continues to seek qualified independent directors. Jordan brings extensive experience, including his current role as CEO of HighMont Advisors Inc. and senior advisor at Evans & Evans, Inc. His previous positions include CFO and interim CEO at Ascent Industries Corp., and he has served on multiple boards across various sectors. Jordan's appointment includes membership on several Board committees and he will receive an annual retainer fee, with half of his compensation deferred until the company raises $1 million. The company will enter into an indemnification agreement with Jordan, similar to those with other directors.
On February 28, 2024, 180 Life Sciences Corp. announced the appointment of Blair Jordan to its Board of Directors. Jordan, deemed independent according to Nasdaq Capital Market rules, will serve as a Class II director until the 2024 Annual Meeting of Stockholders. Concurrently, the Board set its membership at four and continues to seek qualified independent directors. Jordan brings extensive experience, including his current role as CEO of HighMont Advisors Inc. and senior advisor at Evans & Evans, Inc. His previous positions include CFO and interim CEO at Ascent Industries Corp., and he has served on multiple boards across various sectors. Jordan's appointment includes membership on several Board committees and he will receive an annual retainer fee, with half of his compensation deferred until the company raises $1 million. The company will enter into an indemnification agreement with Jordan, similar to those with other directors.
2024 年 2 月 28 日，180 生命科學公司宣佈任命布萊爾·喬丹爲其董事會成員。根據納斯達克資本市場規則，喬丹被視爲獨立董事，將在2024年年度股東大會之前擔任二類董事。同時，董事會將其成員人數定爲四人，並繼續尋找合格的獨立董事。喬丹擁有豐富的經驗，包括他目前擔任HighMont Advisors Inc.首席執行官和埃文斯公司的高級顧問。他之前的職位包括Ascent Industries Corp的首席財務官和臨時首席執行官，並曾在多個行業的董事會任職。喬丹的任命包括多個董事會委員會的成員，他將獲得年度預付費，一半的薪酬將推遲到公司籌集100萬美元之後。該公司將與約旦簽訂賠償協議，類似於與其他董事的補償協議。
2024 年 2 月 28 日，180 生命科學公司宣佈任命布萊爾·喬丹爲其董事會成員。根據納斯達克資本市場規則，喬丹被視爲獨立董事，將在2024年年度股東大會之前擔任二類董事。同時，董事會將其成員人數定爲四人，並繼續尋找合格的獨立董事。喬丹擁有豐富的經驗，包括他目前擔任HighMont Advisors Inc.首席執行官和埃文斯公司的高級顧問。他之前的職位包括Ascent Industries Corp的首席財務官和臨時首席執行官，並曾在多個行業的董事會任職。喬丹的任命包括多個董事會委員會的成員，他將獲得年度預付費，一半的薪酬將推遲到公司籌集100萬美元之後。該公司將與約旦簽訂賠償協議，類似於與其他董事的補償協議。
有用
沒用